Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 1998

View Archived Issues

COX-2 inhibitors reported by UPSA

Polypeptide-chelating agent complexes reported by Novartis

Native calcitonin mimetics from ZymoGenetics

Anti-GnRH immunogens disclosed by Aphton

QLT PhotoTherapeutics: Q3 1997 highlights

Company Profile: Teva

Structurally distinct vitamin D analogues from Leo

Antiamnesic compounds described by Gedeon Richter

NOS inhibitors prepared at Ono

Antifungal agents prepared at Pola

Abelcet now approved in 18 countries

Enrollment complete in pivotal trial of P829 for lung cancer imaging

MMP inhibitor developed at Chiroscience enters clinical trials for cancer

Biomatrix's Hyalform approved in additional markets; PMA resubmission planned in U.S.

Oral ganciclovir tested for prevention of CMV disease in transplant recipients

Synaptic, Merck & Co. extend BPH research agreement

Antiplatelet effects of policosanol, aspirin and policosanol + aspirin in humans

FDA approves first gene-based cancer diagnostic for U.S. market

Clinical pharmacodynamic profile of 5-HT4 agonist

Indian scientists demonstrate protective effect of NAP against stress organ injury in malaria

Lubeluzole improves clinical outcome in stroke patients

Mechanism of TNF-alpha production in tumor tissues by Ono-4007

Nootropic agent evaluated for the treatment of stroke

Anika files for U.S. approval of osteoarthritis Rx

GR-144053 enhances suppression of neointima formation by losartan following vascular injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...